Improved culture methods and devices for testing

Abstract

To provide more efficient cell culture devices and methods.SOLUTION: A cell culture device includes a plurality of compartments. Therein: each compartment is separated from adjacent compartments by a common wall; the wall is joined to a bottom of the compartments; each compartment includes at least one permanently-open passage; the permanently-open passage is an opening passing through the common wall; connecting the bottom of adjacent compartments allows contents of one of the compartments to communicate with another one of the compartments. The geometries can be used to reduce the number of interventions for feeding, increase cell density, allow gradients to be established by cell secreted products, study the mobility of organisms, and / or improve the ability to assess the ability of T cells to find and / or kill cancer cells.SELECTED DRAWING: Figure 3A

Description

[Technical field]

[0001] Related Applications This application claims the benefit of U.S. Provisional Application No. 62 / 158,583, filed May 8, 2015, which is incorporated by reference in its entirety.

[0002] The technical field of the present invention relates generally to cell culture devices. More specifically, the present invention is directed to methods and devices that improve the ability to study cell-cell interactions in vitro by providing unique geometries that can be used to reduce feeding interventions, increase cell density, form cell secretion gradients, study organismal motility, and evaluate the ability of T cells to find and kill cancer cells. [Background technology]

[0003] Current static in vitro cell culture devices used to culture and evaluate cells present at high densities cannot allow long-term culture processes without frequent medium changes to supply nutrients to the cells, which has the adverse effect of frequently altering the concentrations of various cellular secretory signals.

[0004] One example of how problematic the design of existing devices is in the field of T cell therapy, where there is a desire to understand how cytotoxic T cells can migrate to a tumor-type environment, attack cancer cells, and continue their attack. Currently, the typical in vitro approach is to seed cancer cells into conventional multi-well plates, where they are settled into some form of three-dimensional matrix that allows the cancer cells to grow at high density. T cells of a type that can kill the cancer cells are then placed into the multi-well plate, where the ability of the T cells to eradicate the cancer cells is evaluated. The large number of cells that will survive in each well places high metabolic demands on the very small amount of medium in each well. To meet this demand, the medium must be changed frequently. This removes or dilutes important cellular signals involved in the killing process by adding fresh medium. Thus, culture conditions change frequently, which can affect the experimental results. Furthermore, when cancer cells rapidly expand quantitatively, the ability to change the medium frequently enough to meet the metabolic demands of the cancer cells is completely lost, limiting the duration of the experiment to just a few days.

[0005] A commonly used method to avoid this problem is to use severe combined immunodeficient (SCID) mice. To perform the evaluation, cancer cells are introduced into the mouse or cancer cells are created in the mouse. T cells are then introduced into the mouse. The nutritional requirements of the cells can be met by the mouse for a longer period than with traditional in vitro devices, and frequent changes in cell conditions that are characteristic of in vitro devices are avoided. However, even if the mice used are highly controlled, it is difficult to predict the variability between mice.

[0006] The embodiments disclosed herein provide more efficient cell culture devices and methods that overcome the limitations of previous devices and methods by creating devices that can incorporate a variety of novel features. [Prior art documents] [Patent documents]

[0007] [Patent Document 1] U.S. Patent No. 9,255,243 Summary of the Invention

[0008] We have discovered that a uniquely shaped in vitro device provides a superior alternative to existing devices for long-term culture or for moving cells or materials within a culture. This novel stationary device and method of use do not require a medium stirrer, medium perfusion machine, or gas pump device to function.

[0009] Certain embodiments disclosed herein provide an improved cell culture environment in which cells, such as cancer cells, can be grown at high densities without the need for nutrient replenishment as frequently as in existing high density static culture devices. This can be beneficial, for example, when studying the ability of T cells to attack and sustain the attack on cancer cells, without interrupting the attack process with nutrient replenishment for a longer period of time than in existing state-of-the-art devices. The less frequently the process is interrupted to provide nutrients to the culture, including the possibility of not interrupting the process at all, the fewer variables there are to consider when evaluating the results.

[0010] Certain embodiments disclosed herein describe improved geometries compared to existing static cell culture devices that allow for the movement of materials and cells throughout the device. The geometry can be altered to control how components in the medium move between compartments and how cells move between compartments within the device. By modifying the geometry and materials to increase the supply of nutrients and oxygen, various processes involving cells can be studied over extended periods of time.

[0011] Such embodiments can be used to assess over time the ability of cells to generate signals, respond to signals, and migrate to the source of the signal. For example, cancer cells cultured at high density can be the source of a chemokine signal. The signal travels through a labyrinth of compartments until it finally reaches a T cell in the device, where the T cell responds and migrates through the labyrinth until it finds the source of the signal. Once the T cell finds the cancer cell as the source, it can initiate and continue killing the cancer cells. The geometry can be appropriately structured to allow this process to proceed without being hindered by feeding or by physical forces within the medium that may result from moving through the device. The device can also be structured to allow the process to be observed visually.

[0012] In such an embodiment, the ability of the engineered T cells to find and kill the targeted cancer cells and sustain the killing of the targeted cancer cells. The geometry of the device allows for comparison with T cell populations with other engineered characteristics. They can allow for the evaluation of how well engineered T cells respond to different types of cancer cells. They also allow for the evaluation of how natural T cells respond to tumor associated antigens.

[0013] In such embodiments, the ability of a substance of interest to move between compartments can be altered, the pathway along which the substance moves can be altered, or the pathway along which the substance moves can be opened or closed.

[0014] Certain embodiments disclosed herein provide more efficient cell culture devices that can incorporate a variety of novel features, including the use of gas permeable materials, greater medium capacity than previous devices, compartments that can reduce disturbances to the culture environment to facilitate long-term study of high density cultures, and the ability to study the movement of objects of interest, including substances such as chemokines, track cell movement, and observe cell-cell interactions. [Brief description of the drawings]

[0015] [Figure 1] FIG. 1 shows a cross-sectional view of one embodiment that allows for long-term culture, which may be beneficial for a variety of cell culture applications, including studies of the ability of T cells to kill and sustain the killing of cancer cells. [Diagram 2] 2A, 2B and 2C show various views of a compartmentalized device containing two compartments. [Diagram 3] Figures 3A, 3B and 3C show one example of how the device shown in Figures 2A, 2B and 2C above can be compartmentalized and used. [Figure 4] FIG. 4 shows a plan view of the device compartmentalized into three compartments. [Diagram 5] 5A, 5B and 5C each show a perspective view of a possible configuration of a six compartment device of the present invention. [Figure 6] FIG. 6 shows a circular configuration of the present invention that includes pie-shaped sections. [Figure 7] FIG. 7 shows a circular configuration of the present invention that includes pie-shaped sections. [Figure 8] FIG. 8 shows an embodiment of a device subdivided into non-symmetrical compartments. [Figure 9] FIG. 9 shows one possible channel configuration that can be used to minimize medium transfer between compartments. [Figure 10] FIG. 10 shows an alternative passageway configuration that can be used to minimize medium transfer between compartments. [Figure 11]FIG. 11 illustrates that the compartment walls can be any shape and any amount of material can be removed from them as needed for a particular application. [Figure 12] Figure 12 shows representative examples of cancer cell proliferation in SCID mice and prototypes, as indicated by a gradually increasing bioluminescent signal over a 28-day period. Figure 12B compares cancer cell growth in prototypes, SCID mice, and plates in the AlgiMatrix® 3D culture system. [Figure 13] FIG. 13 shows that cancer cells cultured in plates of a conventional AlgiMatrix® 3D culture system rapidly exhausted the supplied nutrients and died by day 7. [Figure 14] FIG. 14 shows that administration of CAR-T cells to SCID mice resulted in a reduction in tumor signal that persisted for 2 weeks, and the same anti-tumor effect was seen when CAR-T cells were added directly to the test prototype of the present invention. [Figure 15] FIG. 15 shows that the present invention is capable of creating chemokine gradients across the device. [Figure 16] FIG. 16 shows that the data suggests that the present invention can be used to distinguish between first and second generation CAR-T cells. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0016] FIG. 1 shows a cross-sectional view of one embodiment of the present invention, showing the device without integration of a medium stirrer, medium perfusion machine, or gas pump. This device can be used to culture cancer cells at high density and study the ability of T cells to kill and sustain the killing of cancer cells. Cancer cells 1 are present at the bottom of a static cell culture device 2. The top is not shown, but can be as simple as a cover commonly used for multi-well plates, or more advanced, including closed structures for automated access. The cancer cell culture device 2 contains culture medium 3. The bottom 4 of the device is made of a gas permeable material, preferably silicone. The surface that the cells contact at the bottom of the compartment can be modified, for example by texturing, to allow cancer cells to survive at high density to simulate a tumor. The surface structure can be grooved, pocketed, roughened, etc. Essentially, a rough bottom surface allows a larger surface area for the cancer cells to contact than a smooth bottom surface of the device, promoting the proliferation of more cells per square centimeter of the bottom of the compartment. Matrices can also be used to culture cells at high density or in a more natural physical structure. Matrices are often used to culture cells in what is generally referred to as 3D culture. The matrix can be attached to the bottom surface, but does not necessarily have to be attached to the bottom surface. The matrix material can be made of any material known to those skilled in the art that allows cells to be cultured in a state where they can be in close contact with the matrix or integrated within the matrix. Such materials can be selected from a number of options, including natural or synthetic materials such as AlgiMatrix®, collagen, fibronectin, plastics, sintered ceramics, etc. Such materials must be compatible in that they allow cells to be in close contact (e.g., when using cancer cells to simulate a tumor) and allow oxygen to reach the cells, if the bottom is gas permeable. Therefore, it is preferable that the matrix is ​​not a solid material.

[0017] This embodiment overcomes the limitations of conventional in vitro culture devices, such as the 24-well plate of the AlgiMatrix® 3D culture system (Gibco catalog number 12684-023). By providing a large volume of medium as well as an excellent oxygen supply through the gas permeable bottom, T cells can be added to the device and the ability of the T cells to kill cancer cells can be evaluated over a long period of time. By ensuring that the ratio of the volume to the bottom area of ​​the medium exceeds that of the 24-well plate of the AlgiMatrix® 3D culture system, the device can function in many ways more advantageously over a longer period of time, as will be shown later. This bottom area is determined by calculating the bottom area assuming a smooth bottom surface. This avoids taking into account surface textures and other shapes of the growth matrix and additional areas. It is desirable to have a ratio of the volume to the bottom area of ​​the medium exceed that of the 24-well plate of the AlgiMatrix® 3D culture system. Thus, in a preferred embodiment, the ratio of medium volume to bottom surface area is 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, or any value therebetween. The bottom is preferably made of silicone. Also, to improve the performance of evaluating cell activity within the device, particularly by fluorescence detection, at least the walls should be colored. The bottom is preferably colored as well, and both the walls and bottom can be colored.

[0018] FIG. 2A shows a plan view of a compartmentalized device 10, including two compartments. The top has been removed for clarity. Although the perimeter of each compartment is shown as a square, they can be any shape, and each compartment need not have the same shape or area. A passageway 14 connects compartment 11 to adjacent compartment 12, as best seen in FIG. 2B, a cross-sectional view between A and B of FIG. 2A. In FIG. 2B, the compartments are shown with a top 13, which can be similar to the top of a conventional multiwell plate. The bottom of the compartment can be gas impermeable or gas permeable. If gas permeable, the material should desirably be liquid impermeable. By making the bottom 15 of each compartment gas permeable, no gaps need be provided in the top 13 to allow gas to pass into the compartment, and the top 13 can be tightly fitted to the device to minimize the risk of contamination. In FIG. 2B, the top 13 is shown resting on top, similar to the top of a conventional multiwell plate. Feet 5 can be used to raise the bottom of the compartment. This serves one or more purposes. For example, if one wishes to assess the contents of the compartment through the bottom (such as with an inverted microscope), the feet can ensure that the bottom is not scratched or otherwise impairs the ease of assessment. If one wishes to use a gas permeable material at the bottom of one or more compartments, the feet can raise the bottom to an elevated position to facilitate spontaneous contact of the surrounding gas with the gas permeable material. If the bottom is gas permeable, the bottom can be in contact with the surrounding gas without the need to forcefully move the gas, such as by pumping it, to contact the gas permeable material. To learn more about techniques for allowing the surrounding gas to non-actively and non-forcefully contact the gas permeable material while at the same time maintaining the gas permeable material on a horizontal surface, one of skill in the art is advised to read U.S. Pat. No. 9,255,243, which is incorporated herein by reference in its entirety. FIG. 2C shows a cross-sectional view BB of FIG. 2A. In this Figure 2C, passageway 14 is an opening in the wall separating adjacent compartments 11 and 12. Passageway 14 can be any opening that allows the contents of one compartment to communicate with the other compartment.

[0019] Figures 3A, 3B, and 3C show an example of how the compartmentalized device 10 shown in Figures 2A, 2B, and 2C above can be used. The geometry of this device allows the ability of T cells to recognize and follow a chemokine gradient, find cancer cells, initiate and continue the killing of the cancer cells to be evaluated. As shown in Figure 3A, cancer cells 16 are present in compartment 11 and T cells 18 are present in compartment 12. Arrow 20 indicates the direction of movement of chemokines secreted by cancer cells 16 through passage 14 as they move from a place of high concentration to a place of low concentration. Arrow 22 in Figure 3B indicates the direction of movement of T cells through passage 14 as they move from a place of low concentration to a place of high concentration in search of a source of chemokines. Figure 3C shows how T cells have migrated to compartment 11 in search of cancer cells 16. For clarity, the presence of culture medium has not been shown. This device geometry allows the assessment of the ability of T cells to recognize a chemokine gradient, follow that gradient, find cancer cells, initiate cancer cell killing, and sustain cancer cell killing.

[0020] Various design features can be used to alter the performance of the device or optimize its performance for a particular application. Examples can help illustrate how design features can be altered to better suit the device's performance for a specific application. An example would be an application in which the user of the device is attempting to evaluate the ability of T cells to find and kill cancer cells. An important aspect of the device for this application is the shape of the bottom of each compartment. In the compartments where cancer cells are present, the cancer cells should be grown at high density to simulate a tumor. In areas of the device where cancer cells are not present, the design goal should be to create an environment that does not impede the migration of the T cells to the location of the cancer cells. Therefore, the surface through which the T cells pass should be flat and non-textured. A smooth surface finish should have a flat, uniform hardness and no noticeable protrusions, bumps, or burrs. A Society of Plastics Engineers (SPE) surface finish of No. 2 is more preferred, and SPE surface finish No. 1 is most preferred. Additionally, the surface across which the cells move during use of the device should be generally horizontal. This is to minimize the possibility of the cells moving uphill or downhill due to gravity. Either of these situations can mislead researchers into thinking that the T cells are moving faster or slower than they would actually if the surface were horizontal. The intent is to motivate the T cells towards the cancer cells via chemokine stimulation so that the T cells can be evaluated for their ability to find the cancer cells. Thus, the intent of this design is to minimize unnecessary forces that either tend to motivate the T cells towards the cancer cells or weaken their ability to migrate towards the cancer cells. Those skilled in the art will recognize that a perfectly horizontal surface is unlikely, but surfaces similar to those commonly found on conventional multi-well plates or the commercially available G-Rex® device are suitable. Unwanted forces include not only the effects of gravity, but also the inertia of the medium as the device moves. The various designs of the passageways and the location of the passageways are discussed in detail below to minimize the effects of inertia.Furthermore, if cell migration is desired, it is desirable that the material expected to come into contact with the cells in the passageway along which the cells are expected to migrate is hydrophobic so as to facilitate cell migration, or in other words, if cell migration is desired, the material that comes into contact with the migrating cells should not be a material to which the cells can adhere.

[0021] The bottom of each compartment can be made of any material used in cell culture and does not need to be gas permeable. Examples of such materials include polystyrene of thicknesses commonly found in conventional multi-well plates. However, as described below, we have discovered that using a gas permeable material for the bottom can provide advantages. The material can be a membrane, film, or the like, or can be a material used in gas permeable cell culture devices, such as silicone, fluoroethylene polypropylene, polyolefin, polystyrene, and ethylene vinyl acetate copolymer. As will be appreciated by those skilled in the art, the gas permeable material should be selected based on a variety of properties including gas permeability, moisture permeability, ability to change for desired cell-cell interactions, optical clarity, physical strength, and the like. There is a wide range of information describing the types of gas permeable materials that have been used successfully in cell culture. Silicone is a desirable choice. Silicone has good oxygen permeability, allows optical observation, is not easily punctured, does not typically support cell adhesion, and can be easily molded into a variety of shapes suitable for the present invention.

[0022] The wall height determines how much medium can enter the device. Adding medium provides a larger source of substrate and a larger waste reservoir. Increasing the wall height and allowing a larger volume of medium into the compartment has the effect of reducing feeding frequency and reducing fluctuations in the concentration of solutes and substances in the medium. This also has the effect of increasing the number of cells present per square centimeter of base area of ​​the device.

[0023] Also, one may wish to use more than one compartment. Figure 4 shows a plan view of a compartmentalized device with three compartments. For clarity, non-relevant components of the compartment boundaries and pathways between the compartments are not shown. This configuration can be used to evaluate the ability of different T cell populations to recognize various types of cancer cells. For example, cancer cells from one type of cancer can be placed in compartment 24 of the compartmentalized device 23. One T cell population can be placed in compartment 25 and another T cell population can be placed in compartment 26. When the cancer cells secrete a chemokine signal, one can observe which type of T cell is best able to respond to and migrate to the cancer cells. Such evaluation can be useful, for example, when evaluating T cell populations that have been genetically engineered to have different properties. In this configuration, the genetically engineered T cell population that migrates to the cancer cells the fastest can be useful to evaluate how well the genetically engineered properties are predicted to work in vivo.

[0024] To ensure that differences in T cell responses are due to the T cells and not due to the shape or type of material within the compartments, compartments 25 and 26 are preferably made with consideration to providing the same shape and the same material. Thus, compartments 25 and 26 are preferably of the same shape and material. A key feature is the placement of the passageway between the compartments. Those skilled in the art should be aware that there need not be only one passageway between the compartments. In this figure, only one passageway is shown for clarity. The passageway between compartments 25 and 24 is preferably formed in the same shape as the passageway between compartments 26 and 24. An important consideration when designing the passageway is to place the passageway in the same relationship to compartment 24. For example, passageway 27 in FIG. 4 is in the center of the wall separating compartment 25 from compartment 24, and passageway 28 is in the center of the wall separating compartment 26 from compartment 24. Assuming that the cancer cells are uniformly distributed throughout each compartment, this helps ensure that the chemokine signal reaches the T cells at approximately the same time and with approximately the same signal concentration.

[0025] Another application of the geometry shown in FIG. 4 is to place T cells in compartment 24, followed by two different types of cancer cells in compartments 25 and 26. In this configuration, T cells can be evaluated for their response to and migration towards different types of cancer cells. This application can be particularly useful when evaluating a T cell population of T cells that recognize one or more tumor-associated antigens for their ability to recognize different types of tumors, such as a population of cancer cells. Also, in any of the embodiments herein, actual tumor fragments can be used in place of cancer cells when evaluating the ability to recognize and kill cancer cells.

[0026] The number of compartments can be 1, 2, 3, 4, 5, 6 or more. As mentioned above, the shape of the compartments is not limited to a square or a rectangle. Figures 5A, 5B and 5C each show a perspective view of a possible shape of the six compartment device of the present invention. The passages between the individual compartments can be formed in various patterns to allow the movement of mobile substances, such as chemokines and cells, or microorganisms between the compartments. In each of the shapes shown, arrow 29 indicates the path of movement, which begins in compartment 30 and ends where the arrowhead of arrow 29 ends. The specific layout of the passages is not shown in Figures 5A, 5B and 5C in order to focus on the fact that the location of the passages can create various paths between the compartments. Some paths can minimize the momentum of the medium when moving the device compared to other paths and minimize the possibility of signals being transmitted from compartment to compartment due to the movement of liquid during operation of the device. In the figures, each arrow changes direction at one or more points. Thus, when a device is constructed with one well expected to be a source of a signal secreted by a cell and one well expected to contain cells responsive to the source of the signal secreted by the cell, it is desirable that the path between the individual wells is not perfectly straight, and the path of the signal should preferably have at least one change in direction, for example as shown in Figure 5A, and more preferably have one or more changes in direction, for example as shown in Figure 5B, and even more preferably have a change in direction in each of the compartments that are not the source of the signal or the final destination of the signal, as shown in the example of Figure 5C.

[0027] 6 shows the circular configuration of the present invention with pie-shaped compartments. For clarity, only the compartment outlines and passages are shown. Within compartmentalized device 32, compartment 33 is connected to compartment 34 by passage 37, compartment 34 is connected to compartment 35 by passage 36, and compartment 35 is connected to compartment 33 by passage 38. In this configuration, each compartment communicates with each adjacent compartment by a passage.

[0028] 7 shows a circular configuration of the present invention including pie-shaped compartments. For clarity, only the compartment outlines and passageways are shown. Within compartmentalized device 40, compartment 41, compartment 42, and compartment 43 are all connected by passageway 44. This is one illustrative example of how connecting two or more compartments by only one passageway can be accomplished if it is determined to be beneficial.

[0029] 8 shows an embodiment of a compartmentalized device subdivided into asymmetric compartments. Compartmentalized device 46 includes compartments 47, 48, 49, and 50. Passages 51, 52, and 53 allow for mass transfer between compartments 49 and 50. The locations of the passages relative to the center point of the device vary, allowing for longer transfer paths without increasing the footprint of the device.

[0030] The shape, number, and orientation of the passages separating the compartments can affect performance. Their design must balance the need to allow components in the device contents to pass from compartment to compartment with the need to minimize the physical forces that propel the components from one compartment to the other. For example, if T cells are being observed for their ability to find cancer cells, the act of moving the device to observe the event should not itself facilitate that event. It should be noted that the number of passages between compartments need not be limited to only one. Any number of passages can be used, such as 1, 2, 3, 4, 5, 6, etc. The design of the passages between wells can also affect the movement of T cells. For example, when moving the device from a flow hood to an incubator, the amount of medium that moves through the passages to the adjacent compartment should be minimized to prevent the inertia of the medium from causing the T cells to flow from one compartment to the other or the cancer cells to flow from one compartment to the other. This can be achieved in a variety of ways.

[0031] 9 shows one configuration of passageways that can be used to minimize medium movement between compartments. Walls 58 and 59 of passageway 56 do not form a path vertically through compartment wall 55, whereas walls 60 and 61 of passageway 57 do form a path vertically through compartment wall 55. Either passageway can be used, but in this case passageway 56 can be used to provide resistance to medium inertia during operation of the device.

[0032] 10 illustrates another configuration of passageways that can be used to minimize medium movement between compartments. Passageway 63 does not form a path vertically through compartment wall 62. Instead, passageway 63 includes two right angle turns within compartment wall 62. Those skilled in the art will recognize that at least one turn of any angle can be used in the passageway to limit material flow through the compartment wall due to inertia.

[0033] FIG. 11 shows that the passages can be any shape and any amount of material can be removed from the partition wall as required for a particular application. For example, passage 65 is rectangular, passage 67 is rectangular with a circular top, and passage 68 is triangular. Passage 66 is a gap that passes completely through partition wall 69. Partition wall 69 is connected to bottom 70. If the partition wall is molded integrally with the bottom, it is advantageous to provide a gap that passes completely through the partition wall. A second member can then be attached to the partition wall to close a portion of the gap, if necessary. In this case, the partition wall includes a first wall with an opening and a wall member that narrows the opening. The size of the opening is reduced by the wall member. Those skilled in the art will recognize that more than one passage can be used in a partition wall, and that each passage can vary in shape, size, and cross-sectional area to suit a given application.

[0034] The passageway does not have to be open all the time. The passageway can have a closure that prevents the contents of the compartment from passing through the wall. The closure can be opened when it is desired to allow the contents of the compartment to flow through the passageway.

[0035] For experiments where one wishes to observe the fluorescence of a substance or object, it may be beneficial to have the walls and / or base of the compartment not be optically transparent. If plastic, a colorant may be included in the material. The choice of material for the walls and base is also a consideration. A preferred method of manufacture is to manufacture the walls and base from silicone. A more preferred method of manufacture is to injection mold the walls and base and bond them in the process. For applications involving the observation of fluorescent markers, it may be beneficial to use a colorant in the silicone. It may also be practical to overmold a silicone base onto the colored walls of the compartment. In this way, the walls can be colored while the silicone base is optically transparent.

[0036] The invention will now be further described with reference to the following non-limiting examples.

[0037] Example 1 This novel device offers advantages for studying cancer cells compared to commonly used conventional in vitro devices and SCID mice.

[0038] An evaluation was conducted to determine whether the compartmentalized device of the present invention could support cancer cells in a manner superior to standard in vitro devices commonly used for cancer cell culture, and the evaluation included comparison with in vivo culture of cancer cells in SCID mice.

[0039] A prototype of one embodiment of the compartmentalized device was constructed. The device containing the cancer cells has an area of ​​12 cm. 2 The compartments had a square base of 0.008 to 0.012 in. thick silicone. The compartment walls were high enough to accommodate a 5 cm height of medium, which was placed directly on top of the base.

[0040] To confirm that this novel approach can support tumor growth over time, we compared this prototype to 24-well plates in the AlgiMatrix® 3D culture system (Gibco Catalog No. 12684-023), a system commonly used to study cancer cells, and to SCID mice. To begin this comparison, we first cultured 1×10 cells of the cancer cell line CAPAN-1 in each of six wells of a 24-well plate in the AlgiMatrix® 3D culture system. 6 Approximately 24 hours later, after the cancer cells had taken root in the AlgiMatrix® bioscaffolds, the three bioscaffolds were removed and placed individually in each of the three prototypes. That is, each prototype now had one AlgiMatrix® bioscaffold with cancer cells taking root. Each prototype was filled with 60 ml of medium, and 2 ml of fresh medium was added sufficiently to each of the three remaining wells in the plate of the AlgiMatrix® 3D culture system. Each of the 20 SCID mice (n=20) was inoculated with 1×10 cells of the cancer cell line CAPAN-1. 6 1000 pieces were added. Cancer cell growth was monitored by bioluminescence imaging. Figure 12 shows representative examples of cancer cells grown in SCID mice and prototypes, as indicated by a progressive increase in bioluminescence signal over 28 days. Figure 12 also compares the growth of cancer cells in prototypes, SCID mice, and AlgiMatrix® 3D culture system plates. Cancer cell growth in prototypes was similar to that observed in SCID mice. Note that the three replicates in the prototype were similar, as indicated by the small error bars in the logarithmic scale graph, while cancer cell growth in SCID mice varied widely. As expected, cancer cells cultured in conventional AlgiMatrix® 3D culture system plates quickly exhausted the supplemental nutrients and died by day 7, as shown in Figure 13.

[0041] Example 2 The novel device has the capability to assess long-term anti-tumor effects.

[0042] To investigate whether the antitumor effect of T cells genetically engineered to contain chimeric antigen receptor (CAR T) cells can be measured in the present invention with the same sensitivity and selectivity as that obtained in SCID mice, 1 × 10 cells of the cancer cell line CAPAN1 were added to three prototypes of the configuration of Example 1. 6 XX SCID mice were also transplanted with 1 × 10 6 After engraftment, 20 × 10 6 CAR T cells were added to each prototype and injected into each SCID mouse. As shown in the left panel of Figure 14, administration of CAR T cells to SCID mice resulted in a reduction in tumor signals that persisted for 2 weeks, suggesting that the injected CAR T cells were able to kill the CAPAN-1 cancer cells and generate an antitumor effect. The right panel of Figure 14 shows that the same antitumor effect was observed when CAR T cells were added directly to the prototype. This demonstrates that the novel prototype is a suitable substitute for SCID mice and that researchers can resort to using the in vitro device more frequently instead of SCID mice.

[0043] Example 3 The present invention allows a chemokine gradient to be formed throughout the device.

[0044] The prototype test device consisted of six compartments, each with a base area of ​​12 cm. 2The walls were such that medium was allowed to enter just above the bottom of each compartment to a height of 5 cm. The compartments were arranged in two rows of three compartments in a pattern similar to that of a conventional 6-well plate. Small access openings between each adjacent wall of the compartments allowed the chemokine to move between the compartments. These openings were approximately 2 mm x 2 mm in size and were located at the base of the center of the wall between the connecting compartments. The top panel of Figure 15 shows arrows displaying the expected gradient direction created by the access between the compartments. Essentially, the design is a maze pattern and is intended to allow the device to be moved (e.g., into an incubator) without disrupting the chemokine gradient. To test whether the novel design aids in gradient generation, 24 μg of recombinant MCP1 was added and mixed into one compartment of the device (shown as well #1 in Figure 15). The chemokine concentration in wells 1-6 was then measured at 24, 48, and 72 hours. The lower panel of FIG. 15 shows the concentration of MCP1 in different wells at the indicated time points. As expected, the concentration of MCP1 in well 1 decreased progressively over time, while the concentration of MCP1 increased with passage and was detectable in the compartments along the pathway. For example, the compartments designated as #2 (24 hours), #3 (48 hours), and #4 (72 hours) in FIG. 15 showed increasing amounts of MCP1, with a clear gradient at 72 hours. This indicates that the present invention can aid in the generation of a chemokine gradient, suggesting that the device can be used to generate a chemokine gradient that can reach T cells in remote wells. The T cells in the remote wells can then be assessed for their responsiveness.

[0045] Example 4 The data suggest that it is possible to distinguish between first and second generation CAR T cells using the present invention.

[0046] The prototype design of Example 3 was used to evaluate the ability to target pancreatic cancer cells. 60 ml of medium was placed in each well. The results are shown in Figure 16. Cultures of fluorescent CAPAN-1 cancer cells were placed in compartment 6 of the two prototypes. First generation CAR T cells were placed in compartment number 1 of one prototype. Second generation CAR T cells were placed in compartment number 1 of the other prototype. In both prototypes, the CAR T cells reached the CAPAN-1 cancer cells by following a chemokine gradient transmitted by the CAPAN-1 cancer cells (migration data not shown). Initially, the first and second generation CAR T mutants showed the ability to reduce the fluorescence of the cancer cells, indicating that they were similarly effective in killing the CAPAN-1 cancer cells, and the cancer cells appeared to be mostly eradicated by about day 12. However, after that, the first generation CAR T cells lost their ability to kill the cancer cells and the cancer cells recovered, while the second generation CAR T cells began to show a dramatic improvement in persistence and were able to maintain their antitumor activity. It is important to note that in a conventional in vitro device, it would not have been possible to distinguish these generations of CAR T cells for two important reasons. First, the conventional in vitro device does not allow migration, and the experiment must be started by placing the T cells in the same compartment as the cancer cells. Second, as mentioned above, the conventional in vitro device does not provide enough nutrients for the cells to survive, so the culture cannot be continued for more than two days (see Figure 13). Therefore, it is not possible to observe the attack of T cells against the cancer cells for a long enough period to detect a definitive change in the killing ability over time. If using conventional methods, scientists would only be able to see the change by using SCID mice. Thus, scientists have wasted money and time to obtain important information that can be obtained quickly and cheaply by the present invention. In addition, this example also demonstrates that the use of gas-permeable materials makes it possible to avoid the need for medium replacement for at least 28 days.In the case of the experiment carried out in Example 3, there was a sufficient amount of medium in the device (ie, 60 ml per compartment for 6 compartments = 360 ml), so the medium was not exchanged.

[0047] For short distance cell migration experiments performed over a very short period of time, one of skill in the art will recognize that it may be more cost effective to create a device that does not rely on the use of gas permeable materials or the use of large amounts of medium. In such cases, a device having at least two compartments should be configured with passageways between the compartments to allow signals and cells to move from compartment to compartment. However, as shown in Example 4, the use of gas permeable materials can eliminate the need for medium changes for at least 28 days.

[0048] Those skilled in the art will appreciate that many modifications can be made without departing from the spirit of the present disclosure. Therefore, it is not intended to limit the scope of the present invention to the embodiments shown and described. Rather, the scope of the present invention should be interpreted by the appended claims and their equivalents. Each of the publications, patents, patent applications and references mentioned herein is hereby incorporated by reference in its entirety.

Claims

1. A method for evaluating the ability of T cells to kill cancer cells using a multi-compartment cell culture device, comprising: The multi-compartment cell culture device has a plurality of compartments, and does not require a medium stirrer, a medium perfusion device, and a gas pump device to function; each of the compartments has a bottom made of a gas permeable material; In at least one section, the gas permeable material is smoothly contoured; In one section, the gas permeable material is molded into an uneven shape; The gas permeable bottom of each compartment is flush with Each compartment is separated from the other compartments by a common wall. the common wall has at least one opening that allows fluid at a bottom on one side of the common wall to move to the other side of the common wall; The method comprises: providing cancer cells, T cells, and medium to the multi-compartment cell culture device such that the cancer cells are located in one compartment different from the T cells; A step of statically culturing for a predetermined period of time; Measuring the number of cancer cells and T cells in each compartment; The method comprising:

2. A method according to claim 1, comprising: The method, wherein at least a portion of one compartment of said multi-compartment cell culture device is colored.

3. The method according to claim 1, The method, wherein the walls of said multi-compartment cell culture device are colored.

4. The method of claim 1, comprising: The method wherein the bottom is colored.

5. The method of claim 1, comprising: The method, wherein at least one compartment of the multi-compartment cell culture device comprises a scaffold.

6. The method of claim 1, comprising: The method, wherein the gas permeable material comprises silicone.

7. The method of claim 6, comprising: The silicone is 0.008 to 0.030 inches thick.

8. The method according to claim 7, comprising: The silicone is 0.008 to 0.012 inches thick.

9. The method of claim 1, comprising: Each compartment is capable of holding medium to a height of 5 cm above said bottom.

10. The method of claim 1, comprising: The method wherein said bottom of each compartment has a surface area of ​​12 cm 2 .

11. The method of claim 1, comprising: The method, wherein the predetermined period of time is 1 to 5 days.

12. The method of claim 1, comprising: The method, wherein the predetermined period of time is 1 to 10 days.

13. The method of claim 1, comprising: The method, wherein the predetermined period of time is 1 to 12 days.

14. The method of claim 1, comprising: The method, wherein the predetermined period of time is 1 to 15 days.

15. The method of claim 1, comprising: The method, wherein the predetermined period of time is from 1 to 20 days.

16. The method of claim 1, comprising: The method, wherein the predetermined period of time is 1 to 25 days.

17. The method of claim 1, comprising: The method, wherein the predetermined period of time is from 1 to 28 days.

Images